Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of the Association for Research in Otolaryngology
Published in: Journal of the Association for Research in Otolaryngology 5/2022

24-08-2022 | Gene Therapy in Oncology | Review

Current Advances in Adeno-Associated Virus-Mediated Gene Therapy to Prevent Acquired Hearing Loss

Authors: Fan Wu, Kumar Sambamurti, Suhua Sha

Published in: Journal of the Association for Research in Otolaryngology | Issue 5/2022

Login to get access

Abstract

Adeno-associated viruses (AAVs) are viral vectors that offer an excellent platform for gene therapy due to their safety profile, persistent gene expression in non-dividing cells, target cell specificity, lack of pathogenicity, and low immunogenicity. Recently, gene therapy for genetic hearing loss with AAV transduction has shown promise in animal models. However, AAV transduction for gene silencing or expression to prevent or manage acquired hearing loss is limited. This review provides an overview of AAV as a leading gene delivery vector for treating genetic hearing loss in animal models. We highlight the advantages and shortcomings of AAV for investigating the mechanisms and preventing acquired hearing loss. We predict that AAV-mediated gene manipulation will be able to prevent acquired hearing loss.
Literature
1.
2.
Kros CJ, Steyger PS (2019) Aminoglycoside- and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies. Cold Spring Harb Perspect Med 9
3.
Sha SH, Schacht J (2017) Emerging therapeutic interventions against noise-induced hearing loss. Expert Opin Investig Drugs 26:85–96PubMedCrossRef
4.
Wu PZ, Liberman LD, Bennett K, de Gruttola V, O’Malley JT, Liberman MC (2019) Primary neural degeneration in the human cochlea: evidence for hidden hearing loss in the aging ear. Neuroscience 407:8–20PubMedCrossRef
5.
Brown CS, Emmett SD, Robler SK, Tucci DL (2018) Global hearing loss prevention. Otolaryngol Clin North Am 51:575–592PubMedCrossRef
6.
Guo J, Chai R, Li H, Sun S (2019) Protection of hair cells from ototoxic drug-induced hearing loss. Adv Exp Med Biol 1130:17–36PubMedCrossRef
7.
Nyberg S, Abbott NJ, Shi X, Steyger PS, Dabdoub A (2019) Delivery of therapeutics to the inner ear: the challenge of the blood-labyrinth barrier. Sci Transl Med 11
8.
Akil O, Dyka F, Calvet C, Emptoz A et al (2019) Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. Proc Natl Acad Sci U S A 116:4496–4501PubMedPubMedCentralCrossRef
9.
Gyorgy B, Nist-Lund C, Pan B et al (2019) Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss. Nat Med 25:1123–1130PubMedPubMedCentralCrossRef
10.
Wu J, Solanes P, Nist-Lund C, Spataro S, Shubina-Oleinik O, Marcovich I, Goldberg H, Schneider BL, Holt JR (2021) Single and dual vector gene therapy with AAV9-PHP.B rescues hearing in Tmc1 mutant mice. Mol Ther 29:973–988PubMedCrossRef
11.
Xue Y, Hu X, Wang D et al (2022) Gene editing in a Myo6 semi-dominant mouse model rescues auditory function. Mol Ther 30:105–118PubMedCrossRef
12.
Hastie E, Samulski RJ (2015) Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success—a personal perspective. Hum Gene Ther 26:257–265PubMedPubMedCentralCrossRef
13.
14.
15.
Bankoti K, Generotti C, Hwa T, Wang L, O’Malley BW Jr, Li D (2021) Advances and challenges in adeno-associated viral inner-ear gene therapy for sensorineural hearing loss. Mol Ther Methods Clin Dev 21:209–236PubMedPubMedCentralCrossRef
16.
17.
Hill K, Yuan H, Wang X, Sha SH (2016) Noise-induced loss of hair cells and cochlear synaptopathy are mediated by the activation of AMPK. J Neurosci 36:7497–7510PubMedPubMedCentralCrossRef
18.
Maeda Y, Sheffield AM, Smith RJH (2009) Therapeutic regulation of gene expression in the inner ear using RNA interference. Adv Otorhinolaryngol 66:13–36PubMedPubMedCentral
19.
Mukherjea D, Jajoo S, Kaur T, Sheehan KE, Ramkumar V, Rybak LP (2010) Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat. Antioxid Redox Signal 13:589–598PubMedPubMedCentralCrossRef
20.
Oishi N, Chen FQ, Zheng HW, Sha SH (2013) Intra-tympanic delivery of short interfering RNA into the adult mouse cochlea. Hear Res 296:36–41PubMedCrossRef
21.
Tanaka M, Asaoka M, Yanagawa Y, Hirashima N (2011) Long-term gene-silencing effects of siRNA introduced by single-cell electroporation into postmitotic CNS neurons. Neurochem Res 36:1482–1489PubMedCrossRef
22.
Atchison RW, Casto BC, Hammon WM (1965) Adenovirus-associated defective virus particles. Science 149:754–756PubMedCrossRef
23.
Hoggan MD, Blacklow NR, Rowe WP (1966) Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A 55:1467–1474PubMedPubMedCentralCrossRef
24.
Samulski RJ, Muzyczka N (2014) AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 1:427–451PubMedCrossRef
25.
Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS (2002) The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A 99:10405–10410PubMedPubMedCentralCrossRef
26.
Sonntag F, Köther K, Schmidt K et al (2011) The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J Virol 85:12686–12697PubMedPubMedCentralCrossRef
27.
Earley LF, Powers JM, Adachi K, Baumgart JT, Meyer NL, Xie Q, Chapman MS, Nakai H (2017) Adeno-associated virus (AAV) assembly-activating protein is not an essential requirement for capsid assembly of AAV serotypes 4, 5, and 11. J Virol 91
28.
Grimwood J, Gordon LA, Olsen A et al (2004) The DNA sequence and biology of human chromosome 19. Nature 428:529–535PubMedCrossRef
29.
Tullis GE, Shenk T (2000) Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size. J Virol 74:11511–11521PubMedPubMedCentralCrossRef
30.
Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM (2004) Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78:6381–6388PubMedPubMedCentralCrossRef
31.
32.
33.
Wu Z, Asokan A, Samulski RJ (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14:316–327PubMedCrossRef
34.
Agbandje-McKenna M, Kleinschmidt J (2011) AAV capsid structure and cell interactions. Methods Mol Biol 807:47–92PubMedCrossRef
35.
Ivanchenko MV, Hanlon KS, Hathaway DM, Klein AJ, Peters CW, Li Y, Tamvakologos PI, Nammour J, Maguire CA, Corey DP (2021) AAV-S: a versatile capsid variant for transduction of mouse and primate inner ear. Mol Ther Methods Clin Dev 21:382–398PubMedPubMedCentralCrossRef
36.
Lee EJ, Guenther CM, Suh J (2018) Adeno-associated virus (AAV) vectors: rational design strategies for capsid engineering. Curr Opin Biomed Eng 7:58–63PubMedPubMedCentralCrossRef
37.
Vozenilek AE, Blackburn CMR, Schilke RM, Chandran S, Castore R, Klein RL, Woolard MD (2018) AAV8-mediated overexpression of mPCSK9 in liver differs between male and female mice. Atherosclerosis 278:66–72PubMedPubMedCentralCrossRef
38.
Moretti A, Fonteyne L, Giesert F et al (2020) Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med 26:207–214PubMedPubMedCentralCrossRef
39.
Ikeda Y, Sun Z, Ru X, Vandenberghe LH, Humphreys BD (2018) Efficient gene transfer to kidney mesenchymal cells using a synthetic adeno-associated viral vector. J Am Soc Nephrol 29:2287–2297PubMedPubMedCentralCrossRef
40.
Carvalho LS, Xiao R, Wassmer SJ et al (2018) Synthetic adeno-associated viral vector efficiently targets mouse and nonhuman primate retina in vivo. Hum Gene Ther 29:771–784PubMedPubMedCentralCrossRef
41.
Landegger LD, Pan B, Askew C et al (2017) A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nat Biotechnol 35:280–284PubMedPubMedCentralCrossRef
42.
Chiha W, Bartlett CA, Petratos S, Fitzgerald M, Harvey AR (2020) Intravitreal application of AAV-BDNF or mutant AAV-CRMP2 protects retinal ganglion cells and stabilizes axons and myelin after partial optic nerve injury. Exp Neurol 326:113167PubMedCrossRef
43.
44.
Cronin T, Vandenberghe LH, Hantz P et al (2014) Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med 6:1175–1190PubMedPubMedCentralCrossRef
45.
Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, Schaffer DV (2013) In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 5:189ra176
46.
Isgrig K, McDougald DS, Zhu J, Wang HJ, Bennett J, Chien WW (2019) AAV2.7m8 is a powerful viral vector for inner ear gene therapy. Nat Commun 10:427
47.
48.
Morgenstern JP, Land H (1990) A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res 18:1068PubMedPubMedCentralCrossRef
49.
Van Craenenbroeck K, Vanhoenacker P, Haegeman G (2000) Episomal vectors for gene expression in mammalian cells. Eur J Biochem 267:5665–5678PubMedCrossRef
50.
Gray SJ, Foti SB, Schwartz JW et al (2011) Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 22:1143–1153PubMedPubMedCentralCrossRef
51.
Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, Lahn BT (2010) Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS ONE 5:e10611PubMedPubMedCentralCrossRef
52.
Powell SK, Rivera-Soto R, Gray SJ (2015) Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med 19:49–57PubMedPubMedCentral
53.
Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM (2010) Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 21:1259–1271PubMedPubMedCentralCrossRef
54.
Cecchini S, Virag T, Kotin RM (2011) Reproducible high yields of recombinant adeno-associated virus produced using invertebrate cells in 0.02- to 200-liter cultures. Hum Gene Ther 22:1021–1030PubMedPubMedCentralCrossRef
55.
Thorne BA, Takeya RK, Peluso RW (2009) Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum Gene Ther 20:707–714PubMedCrossRef
56.
57.
Potter M, Lins B, Mietzsch M, Heilbronn R, Van Vliet K, Chipman P, Agbandje-McKenna M, Cleaver BD, Clement N, Byrne BJ, Zolotukhin S (2014) A simplified purification protocol for recombinant adeno-associated virus vectors. Mol Ther Methods Clin Dev 1:14034PubMedPubMedCentralCrossRef
58.
59.
60.
Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, Winther B, Kay MA (1998) The kinetics of rAAV integration in the liver. Nat Genet 19:13–15PubMedCrossRef
61.
Nakai H, Wu X, Fuess S, Storm TA, Munroe D, Montini E, Burgess SM, Grompe M, Kay MA (2005) Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J Virol 79:3606–3614PubMedPubMedCentralCrossRef
62.
Hüser D, Gogol-Döring A, Lutter T, Weger S, Winter K, Hammer E-M, Cathomen T, Reinert K, Heilbronn R (2010) Integration preferences of wildtype AAV-2 for consensus rep-binding sites at numerous loci in the human genome. PLoS Pathog 6:e1000985–e1000985PubMedPubMedCentralCrossRef
63.
Chamberlain K, Riyad JM, Weber T (2016) Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids. Hum Gene Ther Methods 27:1–12PubMedPubMedCentralCrossRef
64.
Akil O (2020) Dual and triple AAV delivery of large therapeutic gene sequences into the inner ear. Hear Res 394:107912PubMedCrossRef
65.
Muhuri M, Maeda Y, Ma H, Ram S, Fitzgerald KA, Tai PW, Gao G (2021) Overcoming innate immune barriers that impede AAV gene therapy vectors. J Clin Invest 131
66.
Ronzitti G, Gross D-A, Mingozzi F (2020) Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol 11
67.
Sun JY, Anand-Jawa V, Chatterjee S, Wong KK (2003) Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 10:964–976PubMedCrossRef
68.
Martino AT, Markusic DM (2020) Immune response mechanisms against AAV vectors in animal models. Mol Ther Methods Clin Dev 17:198–208PubMedCrossRef
69.
70.
Wang L, Calcedo R, Bell P, Lin J, Grant RL, Siegel DL, Wilson JM (2011) Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 22:1389–1401PubMedPubMedCentralCrossRef
71.
Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM, Bartlett JS, Muruve DA (2008) Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol 82:2727–2740PubMedPubMedCentralCrossRef
72.
Rabinowitz J, Chan YK, Samulski RJ (2019) Adeno-associated virus (AAV) versus immune response. Viruses 11
73.
Suzuki J, Hashimoto K, Xiao R, Vandenberghe LH, Liberman MC (2017) Cochlear gene therapy with ancestral AAV in adult mice: complete transduction of inner hair cells without cochlear dysfunction. Sci Rep 7:45524PubMedPubMedCentralCrossRef
74.
75.
Hashimoto K, Hickman TT, Suzuki J, Ji L, Kohrman DC, Corfas G, Liberman MC (2019) Protection from noise-induced cochlear synaptopathy by virally mediated overexpression of NT3. Sci Rep 9:15362PubMedPubMedCentralCrossRef
76.
Ulfendahl M, Scarfone E, Flock A, Le Calvez S, Conradi P (2000) Perilymphatic fluid compartments and intercellular spaces of the inner ear and the organ of Corti. Neuroimage 12:307–313PubMedCrossRef
77.
Richard C, Courbon G, Laroche N, Prades JM, Vico L, Malaval L (2017) Inner ear ossification and mineralization kinetics in human embryonic development — microtomographic and histomorphological study. Sci Rep 7:4825PubMedPubMedCentralCrossRef
78.
Yoshimura H, Shibata SB, Ranum PT, Smith RJH (2018) Enhanced viral-mediated cochlear gene delivery in adult mice by combining canal fenestration with round window membrane inoculation. Sci Rep 8:2980PubMedPubMedCentralCrossRef
79.
Jie H, Tao S, Liu L, Xia L, Charko A, Yu Z, Bance M, Yin S, Robertson GS, Wang J (2015) Cochlear protection against cisplatin by viral transfection of X-linked inhibitor of apoptosis protein across round window membrane. Gene Ther 22:546–552PubMedCrossRef
80.
Chien WW, McDougald DS, Roy S, Fitzgerald TS, Cunningham LL (2015) Cochlear gene transfer mediated by adeno-associated virus: comparison of two surgical approaches. Laryngoscope 125:2557–2564PubMedCrossRef
81.
Shu Y, Tao Y, Wang Z, Tang Y, Li H, Dai P, Gao G, Chen ZY (2016) Identification of adeno-associated viral vectors that target neonatal and adult mammalian inner ear cell subtypes. Hum Gene Ther 27:687–699PubMedPubMedCentralCrossRef
82.
Omichi R, Yoshimura H, Shibata SB, Vandenberghe LH, Smith RJH (2020) Hair cell transduction efficiency of single- and dual-AAV serotypes in adult murine cochleae. Mol Ther Methods Clin Dev 17:1167–1177PubMedPubMedCentralCrossRef
83.
84.
Tao Y, Huang M, Shu Y et al (2018) Delivery of adeno-associated virus vectors in adult mammalian inner-ear cell subtypes without auditory dysfunction. Hum Gene Ther 29:492–506PubMedPubMedCentralCrossRef
85.
Suzuki M, Kaga K (1999) Development of blood-labyrinth barrier in the semicircular canal ampulla of the rat. Hear Res 129:27–34PubMedCrossRef
86.
Suzuki M, Yamasoba T, Kaga K (1998) Development of the blood-labyrinth barrier in the rat. Hear Res 116:107–112PubMedCrossRef
87.
Shibata SB, Ranum PT, Moteki H, Pan B, Goodwin AT, Goodman SS, Abbas PJ, Holt JR, Smith RJH (2016) RNA interference prevents autosomal-dominant hearing loss. Am J Hum Genet 98:1101–1113PubMedPubMedCentralCrossRef
88.
Wang Y, Sun Y, Chang Q, Ahmad S, Zhou B, Kim Y, Li H, Lin X (2013) Early postnatal virus inoculation into the scala media achieved extensive expression of exogenous green fluorescent protein in the inner ear and preserved auditory brainstem response thresholds. J Gene Med 15:123–133PubMedCrossRef
89.
Gyorgy B, Meijer EJ, Ivanchenko MV et al (2019) Gene transfer with AAV9-PHP.B rescues hearing in a mouse model of usher syndrome 3A and transduces hair cells in a non-human primate. Mol Ther Methods Clin Dev 13:1–13PubMedCrossRef
90.
Ivanchenko MV, Hanlon KS, Devine MK, Tenneson K, Emond F, Lafond JF, Kenna MA, Corey DP, Maguire CA (2020) Preclinical testing of AAV9-PHP.B for transgene expression in the non-human primate cochlea. Hear Res 394:107930
91.
Lee J, Nist-Lund C, Solanes P, Goldberg H, Wu J, Pan B, Schneider BL, Holt JR (2020) Efficient viral transduction in mouse inner ear hair cells with utricle injection and AAV9-PHP.B. Hear Res 394:107882
92.
93.
Ho MK, Li X, Wang J, Ohmen JD, Friedman RA (2014) FVB/NJ mice demonstrate a youthful sensitivity to noise-induced hearing loss and provide a useful genetic model for the study of neural hearing loss. Audiol Neurotol Extra 4:1–11PubMedPubMedCentralCrossRef
94.
Wu F, Hill K, Fang Q, He Z, Zheng H, Wang X, Xiong H, Sha SH (2022) Traumatic-noise-induced hair cell death and hearing loss is mediated by activation of CaMKKbeta. Cell Mol Life Sci 79:249PubMedCrossRef
95.
Wang X, Yuan C, Huang B et al (2019) Developing a versatile shotgun cloning strategy for single-vector-based multiplex expression of short interfering RNAs (siRNAs) in mammalian cells. ACS Synthe Bio 8:2092–2105CrossRef
96.
Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol 67:657–685CrossRef
97.
Morrison C (2018) Alnylam prepares to land first RNAi drug approval. Nat Rev Drug Discovery 17:156–157PubMedCrossRef
98.
Bellosta S, Rossi C, Alieva AS, Catapano AL, Corsini A, Baragetti A (2022) Cholesterol lowering biotechnological strategies: from monoclonal antibodies to antisense therapies. a pre-clinical perspective review. Cardiovasc Drugs Ther
99.
Chen H, Xing Y, Xia L, Chen Z, Yin S, Wang J (2018) AAV-mediated NT-3 overexpression protects cochleae against noise-induced synaptopathy. Gene Ther 25:251–259PubMedPubMedCentralCrossRef
100.
Liu Y, Okada T, Shimazaki K et al (2008) Protection against aminoglycoside-induced ototoxicity by regulated AAV vector-mediated GDNF gene transfer into the cochlea. Mol Ther 16:474–480PubMedCrossRef
101.
Zheng G, Zhu Z, Zhu K, Wei J, Jing Y, Duan M (2013) Therapeutic effect of adeno-associated virus (AAV)-mediated ADNF-9 expression on cochlea of kanamycin-deafened guinea pigs. Acta Otolaryngol 133:1022–1029PubMedCrossRef
102.
Akil O, Blits B, Lustig LR, Leake PA (2019) Virally mediated overexpression of glial-derived neurotrophic factor elicits age- and dose-dependent neuronal toxicity and hearing loss. Hum Gene Ther 30:88–105PubMedPubMedCentralCrossRef
103.
Cooper LB, Chan DK, Roediger FC, Shaffer BR, Fraser JF, Musatov S, Selesnick SH, Kaplitt MG (2006) AAV-mediated delivery of the caspase inhibitor XIAP protects against cisplatin ototoxicity. Otol Neurotol 27:484–490PubMedCrossRef
104.
Qi F, Zhang R, Chen J et al (2019) Down-regulation of Cav1.3 in auditory pathway promotes age-related hearing loss by enhancing calcium-mediated oxidative stress in male mice. Aging 11:6490–6502PubMedPubMedCentralCrossRef
105.
Mukherjee S, Kuroiwa M, Oakden W et al (2021) Local magnetic delivery of adeno-associated virus AAV2(quad Y-F)-mediated BDNF gene therapy restores hearing after noise injury. Mol Ther
106.
Gu X, Wang D, Xu Z, Wang J, Guo L, Chai R, Li G, Shu Y, Li H (2021) Prevention of acquired sensorineural hearing loss in mice by in vivo Htra2 gene editing. Genome Biol 22:86PubMedPubMedCentralCrossRef
107.
El Andari J, Grimm D (2021) Production, processing, and characterization of synthetic AAV gene therapy vectors. Biotechnol J 16:e2000025PubMedCrossRef
108.
Penaud-Budloo M, Francois A, Clement N, Ayuso E (2018) Pharmacology of recombinant adeno-associated virus production. Mol Ther Methods Clin Dev 8:166–180CrossRef
Metadata
Title
Current Advances in Adeno-Associated Virus-Mediated Gene Therapy to Prevent Acquired Hearing Loss
Authors
Fan Wu
Kumar Sambamurti
Suhua Sha
Publication date
24-08-2022
Publisher
Springer US
Published in
Journal of the Association for Research in Otolaryngology / Issue 5/2022
Print ISSN: 1525-3961
Electronic ISSN: 1438-7573
DOI
https://doi.org/10.1007/s10162-022-00866-y

Other articles of this Issue 5/2022

Journal of the Association for Research in Otolaryngology 5/2022 Go to the issue

Research Article

No Reduction in the 226-Hz Probe Tone Acoustic Reflex Amplitude Following Severe Inner Hair Cell Loss in Chinchillas

Research Article

Mitigation of Hearing Damage After Repeated Blast Exposures in Animal Model of Chinchilla

Editorial

Editorial: Christopher R. Cederroth to take JARO’s editorial lead after Paul B. Manis.

Research Article

Insights into Inner Ear Function and Disease Through Novel Visualization of the Ductus Reuniens, a Seminal Communication Between Hearing and Balance Mechanisms

Research Article

Sound Induced Vibrations Deform the Organ of Corti Complex in the Low-Frequency Apical Region of the Gerbil Cochlea for Normal Hearing

Research Article

Stimulation Rate and Voice Pitch Perception in Cochlear Implants